Boston Scientific Corporation (BSX)

NYSE: BSX · Real-Time Price · USD
103.14
+0.18 (0.17%)
At close: Aug 8, 2025, 4:00 PM
103.04
-0.10 (-0.10%)
After-hours: Aug 8, 2025, 7:45 PM EDT
0.17%
Market Cap152.83B
Revenue (ttm)18.49B
Net Income (ttm)2.51B
Shares Out 1.48B
EPS (ttm)1.68
PE Ratio61.39
Forward PE33.19
Dividendn/a
Ex-Dividend Daten/a
Volume5,075,922
Open103.27
Previous Close102.96
Day's Range103.11 - 104.46
52-Week Range74.01 - 108.94
Beta0.66
AnalystsStrong Buy
Price Target118.32 (+14.72%)
Earnings DateJul 23, 2025

About BSX

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]

Sector Healthcare
IPO Date May 18, 1992
Employees 53,000
Stock Exchange NYSE
Ticker Symbol BSX
Full Company Profile

Financial Performance

In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.

Financial Statements

Analyst Summary

According to 22 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price target is $118.32, which is an increase of 14.72% from the latest price.

Price Target
$118.32
(14.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Boston Scientific Corporation Is Expensive But Worth It

Boston Scientific is a 'forever stock' due to management foresight, robust R&D, and leadership in AI-driven medical devices. Despite a weak valuation grade, its strong financials, global expansion, an...

1 day ago - Seeking Alpha

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...

2 days ago - Seeking Alpha

Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions

LONDON & BOSTON--(BUSINESS WIRE)--Keyron appoints former FDA and Boston Scientific leaders as ForePass—a breakthrough device for severe metabolic disease—prepares for clinical trials.

4 days ago - Business Wire

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

All but two of the S&P 500's sectors are up so far in 2025.

10 days ago - Market Watch

Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript

Boston Scientific Corporation (NYSE:BSX) Q2 2025 Earnings Conference Call July 23, 2025 8:00 AM ET Company Participants Jonathan R. Monson - Executive VP & CFO Kenneth M.

17 days ago - Seeking Alpha

Cramer's Stop Trading: Boston Scientific

Jim Cramer breaks down why he's keeping an eye on shares of Boston Scientific.

17 days ago - CNBC Television

Boston Scientific lifts annual profit view on steady heart devices demand

Boston Scientific raised its annual profit forecast on Wednesday, after strong demand for its heart devices helped the U.S. medical device maker beat second-quarter profit estimates.

18 days ago - Reuters

Boston Scientific announces results for second quarter 2025

MARLBOROUGH, Mass. , July 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reported...

18 days ago - PRNewsWire

How To Trade Boston Scientific Stock Ahead Of Its Upcoming Earnings?

Boston Scientific (NYSE:BSX) is set to announce its earnings on Wednesday, July 23, 2025. In the last five years, BSX stock has shown a positive return on the day after earnings announcements in 60% o...

18 days ago - Forbes

North America Ureteroscopes Market Outlook Report 2018-2033 with an Overview of Key Companies - Boston Scientific, KARL STORZ, Olympus, PENTAX Medical, and Richard Wolf

Explore the "North America Ureteroscopes Market Outlook to 2033" for key insights into the Ureteroscopes market. The report covers annualized market revenues, volume, and average prices across segment...

4 weeks ago - GlobeNewsWire

Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass. , July 7, 2025 /PRNewswire/ -- Boston Scientific...

4 weeks ago - PRNewsWire

Boston Scientific announces conference call discussing second quarter 2025 results

MARLBOROUGH, Mass. , July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter...

5 weeks ago - PRNewsWire

I'm Buying Dividend Aristocrats At Bargain Basement Prices

Now is an opportune time to focus on income stocks like that offer value and stability amid market volatility. I focus on 2 Dividend Aristocrats that are attractively valued while supporting well-cove...

Other symbols: JNJKOMDTPEP
7 weeks ago - Seeking Alpha

What's Happening With Boston Scientific Stock?

Boston Scientific (NYSE:BSX) has experienced a stock price increase of over 30% in the last twelve months, greatly exceeding the S&P 500's gain of 9%. This remarkable performance can be credited to th...

7 weeks ago - Forbes

20 stocks bucking bad trends on Wall Street — what might be next for them?

Analysts have been cutting their estimates for companies' sales and profits, but there are always exceptions to trends.

Other symbols: AMTANETAVGOTRMBBACCCCL
2 months ago - Market Watch

3 Growth Stocks That Aren't the Magnificent 7

Growth-oriented investors have been able to operate on autopilot, but tomorrow's winners might not look like yesterday's.

Other symbols: CYBR
2 months ago - Barrons

Boston Scientific: Old, Reliable; Buy For Their Consistent Growth

Boston Scientific is a global leader in medical devices, excelling in both MedSurg and Cardiovascular segments with consistent, industry-beating growth. Q1 2024 was a record quarter, with 21% YoY reve...

2 months ago - Seeking Alpha

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook

Boston Scientific Corporation BSX is pulling the plug on its ACURATE neo2 and Prime aortic valve systems.

2 months ago - Benzinga

Boston Scientific Corporation (BSX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Boston Scientific Corporation (NYSE:BSX) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 8:01 AM ET Company Participants Michael Mahoney - Chairman and Chief Executive Officer ...

2 months ago - Seeking Alpha

Boston Scientific to not seek US approval for heart device amid regulatory challenges

Boston Scientific said on Wednesday it will stop pursuing U.S. approval for its experimental heart device due to increased clinical and regulatory requirements.

2 months ago - Reuters

Boston Scientific Corporation (BSX) Bank of America's 2025 Health Care Conference (Transcript)

Boston Scientific Corporation (NYSE:BSX) Bank of America's 2025 Health Care Conference May 13, 2025 11:00 AM ET Company Participants Daniel Brennan - EVP & CFO Joe Fitzgerald - EVP & Group President,...

3 months ago - Seeking Alpha

Boston Scientific announces upcoming investor conference schedule

MARLBOROUGH, Mass. , May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May.

3 months ago - PRNewsWire

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

3 months ago - Seeking Alpha

Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints

Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO , April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today ann...

3 months ago - PRNewsWire

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results

Boston Scientific Corporation BSX posted better-than-expected earnings for the first quarter on Wednesday.

3 months ago - Benzinga